MedTrace Logo

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

NCT06277154 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2025-07-24

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.

Conditions

  • Leiomyosarcoma
  • Liposarcoma
  • Synovial Sarcoma
  • Angiosarcoma
  • Undifferentiated Pleomorphic Sarcoma
  • Epithelioid Sarcoma
  • Malignant Peripheral Nerve Sheath Tumors
  • Fibrosarcoma
  • Pleomorphic Rhabdomyosarcoma
  • Endometrial Stromal Sarcoma
  • Desmoplastic Small Round Cell Tumor

Interventions

BIOLOGICAL

MASCT-I

The final products of MASCT-I technology are dendritic cells (DC) and effector T cells.

DRUG

Doxorubicin

Commercially approved for cancer treatment

DRUG

Ifosfamide

Commercially approved for cancer treatment

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • HRYZ Biotech Co.

    lead INDUSTRY

Principal Investigators

  • Xing Zhang · Sun Yat-sen University

  • Zhang Xing · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-21
Primary Completion
2026-02-28
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277154 on ClinicalTrials.gov